Bank of America
VKTX icon

Bank of America’s Viking Therapeutics VKTX Stock Holding History

Bank of America’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-6,700
Closed -$109K – 7964
2023
Q2 		$109K Buy
+6,700
New +$140K ﹤0.01% 6163

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Bank of America's VKTX Position: Q2 2026 in Review

Bank of America increased its Viking Therapeutics (VKTX) stake by 16% in Q2 2026, buying an estimated $1.71M and bringing the position to 383,775 shares worth $15M. The position accounts for ﹤0.01% of the portfolio, ranked #2732.

Bank of America first reported a position in VKTX in Q1 2018 and has held it in 34 quarters since. The position peaked at $33.8M in Q1 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Bank of America held 383,775 shares of Viking Therapeutics worth $15M as of Q2 2026.
  • Bank of America bought 53,055 Viking Therapeutics shares in Q2 2026, an estimated $1.71M.
  • Viking Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #2732 holding.
  • Bank of America first reported a position in Viking Therapeutics in Q1 2018 and has held it in 34 quarters since.
  • Bank of America's Viking Therapeutics position peaked at $33.8M in Q1 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.